Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

86.84USD
23 Mar 2017
Change (% chg)

$-0.58 (-0.66%)
Prev Close
$87.42
Open
$87.31
Day's High
$87.49
Day's Low
$86.73
Volume
386,996
Avg. Vol
423,809
52-wk High
$102.43
52-wk Low
$73.60

Latest Key Developments (Source: Significant Developments)

Biomarin reports Q4 GAAP loss per share $0.53
Thursday, 23 Feb 2017 04:01pm EST 

Biomarin Pharmaceutical Inc : Biomarin announces fourth quarter and full year 2016 financial results . Q4 GAAP loss per share $0.53 . Q4 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S . Qtrly total biomarin revenue $300 million versus $228 million . Sees FY17 total biomarin revenues in range of $1,250 million to $1,300 million . Sees 2017 GAAP net loss $140 million to $180 million . Q4 revenue view $296.0 million -- Thomson Reuters I/B/E/S .Fy2017 revenue view $1.31 billion -- Thomson Reuters I/B/E/S.  Full Article

Jennison Associates Llc reports 5.4 pct passive stake in Biomarin Pharmaceutical
Thursday, 2 Feb 2017 04:46pm EST 

Biomarin Pharmaceutical Inc :Jennison Associates Llc reports 5.4 percent passive stake in Biomarin Pharmaceutical Inc as of Dec 31, 2016- sec filing.  Full Article

Biomarin says receives access to priority medicines regulatory support from EMA
Wednesday, 1 Feb 2017 04:15pm EST 

Biomarin Pharmaceutical Inc :Biomarin receives access to priority medicines (prime) regulatory support from ema for bmn 270 gene therapy in hemophilia a.  Full Article

Biomarin Pharmaceutical enters into a credit agreement
Friday, 2 Dec 2016 04:29pm EST 

Biomarin Pharmaceutical Inc : Biomarin Pharmaceutical Inc - On November 29, 2016, co entered into a credit agreement-SEC filing . Credit agreement provides for up to $100 million in revolving loans, none of which was drawn at closing .Expects to use proceeds of revolving credit facility to finance ongoing working capital needs.  Full Article

BioMarin announces update to Brineura program
Tuesday, 6 Sep 2016 04:05pm EDT 

BioMarin Pharmaceutical Inc : BioMarin announces update to Brineura (cerliponase alfa) program for treatment of CLN2 disease, a form of batten disease . Additional data submitted to BLA following FDA request, PDUFA action date extended to April 27, 2017 . Additional 8 months of treatment (81-week data) show maintenance of efficacy, consistent with previously submitted 48-week data .FDA has not communicated their rationale for declaring submission a major amendment.  Full Article

Biomarin Pharmaceutical announces pricing of public offering of common stock
Tuesday, 9 Aug 2016 09:00am EDT 

Biomarin Pharmaceutical Inc : Biomarin announces pricing of public offering of common stock .Says public offering of 7.50 million common shares priced at $96.00per share.  Full Article

Biomarin Pharmaceutical files for potential mixed shelf offering
Monday, 8 Aug 2016 06:28pm EDT 

Biomarin Pharmaceutical Inc :Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

Biomarin says offering of 7.5 mln shares of stock
Monday, 8 Aug 2016 04:33pm EDT 

Biomarin Pharmaceutical Inc : Biomarin announces public offering of common stock .Says offering of 7.5 million shares of its common stock in an underwritten public offering.  Full Article

Biomarin Pharmaceutical Q2 GAAP loss per share $2.61
Thursday, 4 Aug 2016 04:03pm EDT 

Biomarin Pharmaceutical Inc : Biomarin announces second quarter 2016 financial results . Sees FY 2016 revenue $1.10 billion - $1.15 billion . Q2 GAAP loss per share $2.61 . Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S . Q2 revenue $300.1 million versus i/b/e/s view $278.2 million .FY2016 revenue view $1.09 billion -- Thomson Reuters I/B/E/S.  Full Article

Biomarin withdraws market authorization application for Kyndrisa in Europe
Tuesday, 31 May 2016 04:05pm EDT 

Biomarin Pharmaceutical Inc : Biomarin announces withdrawal of market authorization application for Kyndrisa™ (drisapersen) in Europe . Discussions clearly indicated that CHMP intended to issue a negative opinion .Will continue to explore development of next generation oligonucleotides for treatment of duchenne muscular dystrophy..  Full Article

More From Around the Web

BRIEF-Biomarin reports Q4 GAAP loss per share $0.53

* Biomarin announces fourth quarter and full year 2016 financial results